Design and Synthesis of 4‐Anilinothieno[2,3‐<i>d</i>]pyrimidine‐Based Compounds as Dual EGFR/HER‐2 Inhibitors

Soha R. Abd El Hadi, Deena S. Lasheen, Mahmoud A. Hassan, Khaled A. M. Abouzid

Archiv der Pharmazie · 2016 · 31 citations · 19 references

Concepts

Abstract

Dual inhibition of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER‐2) is an attractive cancer therapeutic approach. In this study, new series of 4‐anilinothieno[2,3‐ d ]pyrimidines were designed, synthesized, and tested as dual EGFR/HER‐2 kinase inhibitors. Five compounds ( 8a , 8b , 8e–g ) demonstrated low to submicromolar inhibition of both kinases with IC 50 values of 1.2, 0.6, 0.3, 0.2, 0.4 μM and 8.2, 3.4, 1.3, 0.5, 2.7 μM for the EGFR and HER‐2, respectively. Introduction of a 5,6‐tetramethylene moiety into the thienopyrimidine core bearing a 4‐(3‐fluorobenzyloxy)‐3‐chloroaniline tail resulted in a favorable increase in both the EGFR and HER‐2 inhibitory activities. Compound 8f (IC 50 EGFR/HER‐2: 0.2/0.5 μM) also exhibited significant cell growth inhibition on some specific NCI cell lines, especially ovarian, breast, non‐small‐cell lung cancer, and renal cancer cell lines.

References

19